Literature DB >> 10418917

Do we need 3 doses of hepatitis B vaccine?

J N Wilson1, D J Nokes.   

Abstract

The hepatitis B virus (HBV) vaccine may provide protection through the clonal expansion of specific memory cells without necessarily having to produce high serum antibody levels. We develop a mathematical model which distinguishes between the accumulation of sensitive memory B and T-helper cells prior to a booster and the high circulating antibody levels present in an individual after a booster. We suggest this immune memory accumulates primarily in an antigen-independent fashion. These phenomena suggest individuals may be immune to infection six months after the priming vaccine dose(s) regardless of whether they receive a booster or not. This hypothesis is supported by immunogenicity data and by two independent vaccine efficacy trials comparing 0, 1 month schedules with 0, 1 and 6 month schedules.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418917     DOI: 10.1016/s0264-410x(99)00029-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Immunological response to two hepatitis B vaccines administered in two different schedules.

Authors:  K M Girisha; J R Kamat; G Nataraj
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

2.  Preventing and treating hepatitis B infection: immunisation is most important strategy to control hepatitis B.

Authors:  Osman David Mansoor; Nick Wilson
Journal:  BMJ       Date:  2005-01-22

3.  Preclinical evaluation of a two-dose vaccination schedule of recombinant Hansenula polymorpha hepatitis B vaccine in animals.

Authors:  Jin Li; Deyou Zhang; Rui Ma; Xuqin Yang; Xi Wang; Caimei Li; Sucai Zhang; Hesheng Xue; Kai Zhao; Hui Zhuang
Journal:  Hum Vaccin Immunother       Date:  2013-01-31       Impact factor: 3.452

4.  Comparison of the accelerated and standard vaccination schedules against hepatitis B in healthcare workers.

Authors:  Keyghobad Ghadiri; Siavash Vaziri; Mandana Afsharian; Alireza Jahanbaksh; Faizolah Mansouri; Mansouri Sayad; Farid Najafi; Bahram Souri
Journal:  J Res Med Sci       Date:  2012-10       Impact factor: 1.852

5.  Explaining observed infection and antibody age-profiles in populations with urogenital schistosomiasis.

Authors:  Kate M Mitchell; Francisca Mutapi; Nicholas J Savill; Mark E J Woolhouse
Journal:  PLoS Comput Biol       Date:  2011-10-20       Impact factor: 4.475

6.  Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation - A Simple Intervention Ensures High Adherence.

Authors:  Toni Herta; David Petroff; Cornelius Engelmann; Adam Herber; Niklas Aehling; Uwe Scheuermann; Michael Bartels; Daniel Seehofer; Thomas Berg; Johannes Wiegand
Journal:  Ann Transplant       Date:  2019-09-13       Impact factor: 1.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.